Silicon Canals
No Result
View All Result
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Exclusive content
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Free Personio whitepaper
    • Guest Contributions
    • Newsletter
    • Partner content
  • Global Jobs
  • Tech Events
  • Partner with us
  • Contact
    • Contact us
    • About us
    • Team
    • Contribute your content
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Exclusive content
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Free Personio whitepaper
    • Guest Contributions
    • Newsletter
    • Partner content
  • Global Jobs
  • Tech Events
  • Partner with us
  • Contact
    • Contact us
    • About us
    • Team
    • Contribute your content
No Result
View All Result
Silicon Canals
No Result
View All Result

Using AI to cure ailments: UK-based BenevolentAI collaborates with AstraZeneca to hasten drug discovery

Editorial team by Editorial team
May 2, 2019
in Startups, Health & Medtech, News, Software & SaaS
Using AI to cure ailments: UK-based BenevolentAI collaborates with AstraZeneca to hasten drug discovery
56
SHARES
LinkedInTwitterWhatsAppFacebook

Artificial Intelligence (AI) is being used for a myriad of applications and healthcare is one such prominent field where it’s applied. While there are numerous companies that employ AI to solve varying problems, the rapidly growing UK-based startup BenevolentAI is one step ahead of the lot.

The company was founded in 2013 with the aim of digging deep into data to find insights and solutions, and to apply them to “to transform the way medicines are discovered, developed, tested and brought to market.”

- Partner content -
HR
Most important HR trends of 2023
HR has a lot of challenges to face in 2023. Find out what they are and how to deal with...Show More
HR has a lot of challenges to face in 2023. Find out what they are and how to deal with them. Show Less
Read more

BenevolentAI has now made a long-term collaboration with AstraZeneca, a US based global pharmaceutical company. The two organisations will employ machine learning and AI for discovery and development of potential new drugs, for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). Here’s how this new partnership aims to accelerate drug discovery and development.

Amalgamating AI with human experience

With this partnership, scientists from BenevolentAI and AstraZeneca will work together. They will use BenevolentAI target identification platform and biomedical knowledge graph and combine it with AstraZeneca’s genomics, chemistry and clinical data. This will enable the machine learning system to analyse data and find insights to understand connections between facts, which were not unknown before.

Additionally, AI-based reasoning is employed to extrapolate previously undiscovered connections. The companies will then together analyse and interpret the results to “understand the underlying mechanisms of these complex diseases and more quickly identify new potential drug targets.”

Joanna Shields, CEO of BenevolentAI, says,“Millions of people today suffer from diseases that have no effective treatment. The future of drug discovery and development lies in bridging the gap between AI, data, and biology. We are thrilled to be joining forces with AstraZeneca to develop new insights and identify promising new treatments for chronic kidney disease and idiopathic pulmonary fibrosis.”

CKD and IPF are complicated diseases in which the underlying disease biology is said to be poorly understood. Therefore, this disease complexity is said to require the interrogation of vast, rich datasets. This partnership thus will help discover more about the diseases and hopefully, improve the chances of developing treatments for them.

Stay tuned to Silicon Canals for more updates in the tech startup world.

Scaling up in Europe: 5 do’s and don’ts of doing business in the Netherlands

 - Partner content -
How to improve your open source security?
How to improve your open source security?
Follow these three steps and get on the path to stronger security practices.Show More
Follow these three steps and get on the path to stronger security practices.Show Less
Read more
Tags: healthtechstart-up
Share4Tweet14SendShare22

Advertise with us | Schedule meeting

Thank you for visiting Silicon Canals! If you want to advertise with us, schedule a meeting.

Featured | Tech Events

Current Month

march

30marAll Day31TNW ValènciaJoin us in the hidden tech gem of the Mediterranean.

Event Details

The Next Web is bringing its renowned tech festival to the Mediterranean on March 30 & 31 with TNW València. Join industry leaders, investors, startups and tech

Event Details

The Next Web is bringing its renowned tech festival to the Mediterranean on March 30 & 31 with TNW València. Join industry leaders, investors, startups and tech enthusiasts to explore the future of tech. Enjoy the fun energy of a music festival with the innovation of a tech conference all in one.

Use discount code SILICONCANALS15 for 15% off your Business pass, Bootstrap package, Scale-up package and Investor pass today!

Learn More

CalendarGoogleCal

Time

march 30 (Thursday) - 31 (Friday)

Location

La Marina de Valencia

april

True BVKeienbergweg 100, 1101 GH Amsterdam

04apr17:3021:00True x Microsoft ISV Community Meet-up: Growing your ISV on AzureReady to scale the ambition of your ISV / SaaS company and rapidly grow your software on Azure?

Silicon Canals | Jobs


Partner content | Work with us

How Gapstars helps Dutch scaleups to find full-fledged development teams, save money and make an impact

Here’s how Amsterdam-based JetLearn is setting up the next generation for success

As Mobility Lab completes sixth edition, startups start collaborating with first clients

Breaking news from Amsterdam | Partner

Amsterdam-based Chargetrip raises €10M Series A funding; targets routing 25 per cent of EV rides globally

Rubio Impact Ventures’ Machtelt Groothuis on impact investing, need to co-invest, and measuring impact

Dutch firm Topicus acquires Amsterdam-based scaleup Five Degrees Holding: Know more

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy Policy
  • Cookie Policy (UK)
  • Cookie Policy (EU)
  • Terms & Conditions Silicon Canals

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

No Result
View All Result
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Exclusive content
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Free Personio whitepaper
    • Guest Contributions
    • Newsletter
    • Partner content
  • Global Jobs
  • Tech Events
  • Partner with us
  • Contact
    • Contact us
    • About us
    • Team
    • Contribute your content

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

Stay updated with the Silicon Canals daily and weekly newsletters.
We promise we won't spam you. You can choose to unsubscribe anytime.
Stay updated with the Silicon Canals daily and weekly newsletters.
We promise we won't spam you. You can choose to unsubscribe anytime.
X
X